Cronstein B N, Eberle M A, Gruber H E, Levin R I
Department of Medicine, New York University Medical Center, NY 10016.
Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2441-5. doi: 10.1073/pnas.88.6.2441.
Although commonly used to control a variety of inflammatory diseases, the mechanism of action of a low dose of methotrexate remains a mystery. Methotrexate accumulates intracellularly where it may interfere with purine metabolism. Therefore, we determined whether a 48-hr pretreatment with methotrexate affected adenosine release from [14C]adenine-labeled human fibroblasts and umbilical vein endothelial cells. Methotrexate significantly increased adenosine release by fibroblasts from 4 +/- 1% to 31 +/- 6% of total purine released (EC50, 1 nM) and by endothelial cells from 24 +/- 4% to 42 +/- 7%. Methotrexate-enhanced adenosine release from fibroblasts was further increased to 51 +/- 4% (EC50, 6 nM) and from endothelial cells was increased to 58 +/- 5% of total purine released by exposure to stimulated (fMet-Leu-Phe at 0.1 microM) neutrophils. The effect of methotrexate on adenosine release was not due to cytotoxicity since cells treated with maximal concentrations of methotrexate took up [14C]adenine and released 14C-labeled purine (a measure of cell injury) in a manner identical to control cells. Methotrexate treatment of fibroblasts dramatically inhibited adherence to fibroblasts by both unstimulated neutrophils (IC50, 9 nM) and stimulated neutrophils (IC50, 13 nM). Methotrexate treatment inhibited neutrophil adherence by enhancing adenosine release from fibroblasts since digestion of extracellular adenosine by added adenosine deaminase completely abrogated the effect of methotrexate on neutrophil adherence without, itself, affecting adherence. One hypothesis that explains the effect of methotrexate on adenosine release is that, by inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase, methotrexate induces the accumulation of AICAR, the nucleoside precursor of which (5-aminoimidazole-4-carboxamide ribonucleoside referred to hereafter as acadesine) has previously been shown to cause adenosine release from ischemic cardiac tissue. We found that acadesine also promotes adenosine release from and inhibits neutrophil adherence to connective tissue cells. The observation that the antiinflammatory actions of methotrexate are due to the capacity of methotrexate to induce adenosine release may form the basis for the development of an additional class of antiinflammatory drugs.
尽管低剂量甲氨蝶呤常用于控制多种炎症性疾病,但其作用机制仍是个谜。甲氨蝶呤在细胞内蓄积,可能会干扰嘌呤代谢。因此,我们确定用甲氨蝶呤进行48小时预处理是否会影响[14C]腺嘌呤标记的人成纤维细胞和脐静脉内皮细胞释放腺苷。甲氨蝶呤使成纤维细胞释放的腺苷从总嘌呤释放量的4±1%显著增加到31±6%(半数有效浓度,1 nM),使内皮细胞释放的腺苷从24±4%增加到42±7%。通过暴露于受刺激的(0.1 microM的甲酰甲硫氨酸-亮氨酸-苯丙氨酸)中性粒细胞,甲氨蝶呤增强的成纤维细胞腺苷释放进一步增加到51±4%(半数有效浓度,6 nM),内皮细胞的增加到58±5%。甲氨蝶呤对腺苷释放的影响并非由于细胞毒性,因为用最大浓度甲氨蝶呤处理的细胞摄取[14C]腺嘌呤并释放14C标记的嘌呤(细胞损伤的一种度量)的方式与对照细胞相同。甲氨蝶呤处理成纤维细胞显著抑制未受刺激的中性粒细胞(半数抑制浓度,9 nM)和受刺激的中性粒细胞(半数抑制浓度,13 nM)对成纤维细胞的黏附。甲氨蝶呤处理通过增强成纤维细胞释放腺苷来抑制中性粒细胞黏附,因为添加的腺苷脱氨酶消化细胞外腺苷完全消除了甲氨蝶呤对中性粒细胞黏附的影响,而其本身并不影响黏附。一个解释甲氨蝶呤对腺苷释放作用的假说是,通过抑制5-氨基咪唑-4-甲酰胺核糖核苷酸(AICAR)转甲酰酶,甲氨蝶呤诱导AICAR蓄积,其核苷前体(5-氨基咪唑-4-甲酰胺核糖核苷,以下简称阿卡地新)先前已被证明可导致缺血心脏组织释放腺苷。我们发现阿卡地新也促进结缔组织细胞释放腺苷并抑制中性粒细胞对其的黏附。甲氨蝶呤的抗炎作用归因于其诱导腺苷释放的能力这一观察结果可能构成开发另一类抗炎药物的基础。